Rockefeller Capital Management L.P. Acquires 13,081 Shares of Novo Nordisk A/S (NYSE:NVO)

Rockefeller Capital Management L.P. raised its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 497,667 shares of the company's stock after buying an additional 13,081 shares during the period. Rockefeller Capital Management L.P.'s holdings in Novo Nordisk A/S were worth $42,868,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Center for Financial Planning Inc. increased its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the period. Albion Financial Group UT increased its position in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC raised its stake in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after buying an additional 243 shares in the last quarter. Hager Investment Management Services LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $46,000. Finally, Halbert Hargrove Global Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $47,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NVO. BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $135.00.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $4.47 during trading hours on Thursday, reaching $58.41. The company had a trading volume of 22,174,774 shares, compared to its average volume of 5,920,549. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business has a fifty day moving average price of $76.55 and a 200-day moving average price of $92.55. Novo Nordisk A/S has a one year low of $57.36 and a one year high of $148.15. The firm has a market cap of $262.12 billion, a PE ratio of 17.81, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.